{
  "parsed": [
    {
      "model": "claude",
      "raw": "\u2500\u2500\u2500 SECTION 1: DECOMPOSITION \u2500\u2500\u2500\n\n**Sub-questions:**\n1. **What CB1 occupancy regime produces sustained wellbeing without triggering compensatory downregulation?** Key variables: THC dose \u2192 CB1 fractional occupancy \u2192 biased agonism ratio (G-protein vs. \u03b2-arrestin) \u2192 receptor internalization rate vs. recycling rate.\n2. **How does exogenous THC interact with endogenous 2-AG/AEA tone?** Key variables: THC concentration at synapse, 2-AG/AEA basal levels, MAGL/FAAH activity, competitive vs. additive binding dynamics.\n3. **What downstream circuits translate CB1 modulation into sustained mood improvement?** Key variables: HPA axis gain (PVN CB1), mesolimbic dopamine modulation, prefrontal-amygdala connectivity.\n4. **Where is the quantitative crossover from therapeutic to tolerance?** Key variable: receptor internalization rate constant (k_int) vs. synthesis/recycling rate constant (k_recycle).\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS \u2500\u2500\u2500\n\n**CLAIM:** At \u22642.5 mg/day oral THC, peak brain CB1 occupancy reaches ~15-25%, sufficient for G-protein signaling (EC50 ~5-10 nM) but below \u03b2-arrestin recruitment threshold (EC50 ~50-100 nM for \u03949-THC), preserving receptor surface expression.\n**TYPE:** 1\n**CONFIDENCE:** 0.72\n**MECHANISM:** THC's partial agonist profile produces biased signaling at low fractional occupancy; \u03b2-arrestin-2 recruitment requires higher agonist efficacy/occupancy than Gi/o coupling, so sub-saturating doses selectively engage the non-desensitizing pathway.\n**FALSIFIABLE BY:** BRET/FRET assays showing \u03b2-arrestin recruitment EC50 \u2264 G-protein EC50 for THC at CB1, or PET imaging showing >30% occupancy at 2.5 mg producing equivalent tolerance to higher doses.\n\n**CLAIM:** Low-dose THC augments rather than displaces endocannabinoid tone because at 15-25% occupancy, sufficient unoccupied CB1 remains for 2-AG/AEA signaling, and THC may inhibit FAAH at low concentrations (Ki ~5-15 \u03bcM range), mildly elevating AEA.\n**TYPE:** 2\n**CONFIDENCE:** 0.55\n**MECHANISM:** Additive tonic signaling from exogenous partial agonist + endogenous full agonists (2-AG) at non-overlapping receptor populations; possible allosteric facilitation of endocannabinoid binding at neighboring receptors.\n**FALSIFIABLE BY:** Microdialysis showing decreased (not stable/increased) 2-AG/AEA in NAc or PFC during chronic low-dose THC administration.\n\n**CLAIM:** The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int \u00d7 fractional_occupancy. For CB1, k_recycle \u2248 0.02 min\u207b\u00b9, k_int \u2248 0.05 min\u207b\u00b9 at full occupancy. Crossover occurs at ~40-50% sustained occupancy, corresponding to ~10-15 mg/day chronic dosing.\n**TYPE:** 3\n**CONFIDENCE:** 0.45\n**MECHANISM:** CB1 internalization follows agonist-driven \u03b2-arrestin-dependent endocytosis; at low occupancy, the internalization flux (k_int \u00d7 occupied_receptors) remains below the constitutive recycling/synthesis flux, maintaining steady-state surface density.\n**FALSIFIABLE BY:** Quantitative PET (e.g., [\u00b9\u00b9C]OMAR) time-series in humans at graded chronic doses showing tolerance onset at occupancies inconsistent with this model, or CB1 surface density measurements via ex vivo binding showing no occupancy-dependent threshold.\n\n**CLAIM:** HPA axis recalibration via PVN CB1 is a primary mediator of sustained wellbeing, reducing tonic CRH release by ~20-35% over 2-4 weeks, measurable as decreased morning cortisol AUC.\n**TYPE:** 1\n**CONFIDENCE:** 0.62\n**MECHANISM:** CB1 on glutamatergic afferents to PVN CRH neurons provides retrograde inhibition; chronic low-dose enhancement strengthens this brake, lowering stress-axis set-point without ablating acute reactivity.\n**FALSIFIABLE BY:** Chronic low-dose THC failing to reduce salivary cortisol AUC in controlled trials, or CB1 conditional knockout in PVN afferents abolishing wellbeing effects without affecting other endpoints.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS \u2500\u2500\u2500\n\n- **Missing:** Human PET occupancy data at \u22642.5 mg oral THC (existing studies use higher",
      "claims": [
        {
          "statement": "At \u22642.5 mg/day oral THC, peak brain CB1 occupancy reaches ~15-25%, sufficient for G-protein signaling (EC50 ~5-10 nM) but below \u03b2-arrestin recruitment threshold (EC50 ~50-100 nM for \u03949-THC), preserving receptor surface expression.",
          "type": 1,
          "confidence": 0.72,
          "mechanism": "THC's partial agonist profile produces biased signaling at low fractional occupancy; \u03b2-arrestin-2 recruitment requires higher agonist efficacy/occupancy than Gi/o coupling, so sub-saturating doses selectively engage the non-desensitizing pathway.",
          "falsifiable_by": "BRET/FRET assays showing \u03b2-arrestin recruitment EC50 \u2264 G-protein EC50 for THC at CB1, or PET imaging showing >30% occupancy at 2.5 mg producing equivalent tolerance to higher doses."
        },
        {
          "statement": "Low-dose THC augments rather than displaces endocannabinoid tone because at 15-25% occupancy, sufficient unoccupied CB1 remains for 2-AG/AEA signaling, and THC may inhibit FAAH at low concentrations (Ki ~5-15 \u03bcM range), mildly elevating AEA.",
          "type": 2,
          "confidence": 0.55,
          "mechanism": "Additive tonic signaling from exogenous partial agonist + endogenous full agonists (2-AG) at non-overlapping receptor populations; possible allosteric facilitation of endocannabinoid binding at neighboring receptors.",
          "falsifiable_by": "Microdialysis showing decreased (not stable/increased) 2-AG/AEA in NAc or PFC during chronic low-dose THC administration."
        },
        {
          "statement": "The tolerance crossover point is governed by first-order kinetics: therapeutic window persists while k_recycle + k_synthesis > k_int \u00d7 fractional_occupancy. For CB1, k_recycle \u2248 0.02 min\u207b\u00b9, k_int \u2248 0.05 min\u207b\u00b9 at full occupancy. Crossover occurs at ~40-50% sustained occupancy, corresponding to ~10-15 mg/day chronic dosing.",
          "type": 3,
          "confidence": 0.45,
          "mechanism": "CB1 internalization follows agonist-driven \u03b2-arrestin-dependent endocytosis; at low occupancy, the internalization flux (k_int \u00d7 occupied_receptors) remains below the constitutive recycling/synthesis flux, maintaining steady-state surface density.",
          "falsifiable_by": "Quantitative PET (e.g., [\u00b9\u00b9C]OMAR) time-series in humans at graded chronic doses showing tolerance onset at occupancies inconsistent with this model, or CB1 surface density measurements via ex vivo binding showing no occupancy-dependent threshold."
        },
        {
          "statement": "HPA axis recalibration via PVN CB1 is a primary mediator of sustained wellbeing, reducing tonic CRH release by ~20-35% over 2-4 weeks, measurable as decreased morning cortisol AUC.",
          "type": 1,
          "confidence": 0.62,
          "mechanism": "CB1 on glutamatergic afferents to PVN CRH neurons provides retrograde inhibition; chronic low-dose enhancement strengthens this brake, lowering stress-axis set-point without ablating acute reactivity.",
          "falsifiable_by": "Chronic low-dose THC failing to reduce salivary cortisol AUC in controlled trials, or CB1 conditional knockout in PVN afferents abolishing wellbeing effects without affecting other endpoints. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "mistral",
      "raw": "---\n### SECTION 1: DECOMPOSITION\n**Sub-questions:**\n1. How does chronic low-dose THC achieve sub-saturating CB1 occupancy (10\u201330%) without triggering \u03b2-arrestin-mediated downregulation, and what are the kinetic thresholds for this balance?\n2. What are the quantitative relationships between THC dose, 2-AG displacement, and MAGL activity in sustaining endocannabinoid tone?\n3. How does CB1 modulation in the PVN/amygdala recalibrate the HPA axis, and what are the temporal dynamics (weeks) of this recalibration?\n4. What defines the crossover point between therapeutic effects (wellbeing) and tolerance (CB1 internalization), and how does receptor recycling/de novo synthesis govern this?\n\n**Key variables:**\n- THC dose (mg/day) \u2192 CB1 occupancy (%) \u2192 G-protein vs. \u03b2-arrestin bias.\n- 2-AG levels (nM) \u2192 MAGL activity (Vmax/Km) \u2192 tonic signaling.\n- CB1 internalization rate (k_int) vs. recycling/synthesis rate (k_rec).\n- HPA axis gain (CRH/cortisol set-point) \u2192 glutamatergic drive to PVN.\n\n---\n\n### SECTION 2: CLAIMS\n\n**CLAIM 1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) is avoided, preserving cAMP/PKA tone.\n**TYPE:** 1 (mechanistic, testable)\n**CONFIDENCE:** 0.85\n**MECHANISM:** Partial agonism at CB1 maintains receptor sensitivity by favoring G-protein coupling over \u03b2-arrestin, preventing desensitization while enhancing tonic endocannabinoid signaling.\n**FALSIFIABLE BY:** If \u03b2-arrestin recruitment occurs at \u22642.5 mg/day (e.g., via BRET assays in vivo), or if cAMP/PKA signaling is suppressed at this dose.\n\n**CLAIM 2:** The therapeutic index (TD50/ED50) for wellbeing vs. tolerance exceeds 10, with tolerance emerging at ~25 mg/day due to CB1 internalization exceeding recycling/synthesis rates (k_int > k_rec).\n**TYPE:** 0 (quantitative prior alignment)\n**CONFIDENCE:** 0.75\n**MECHANISM:** Tolerance onset is governed by a first-order kinetic crossover point where THC-driven internalization outpaces receptor recovery, reducing surface CB1 density.\n**FALSIFIABLE BY:** If tolerance ED50 <25 mg/day (e.g., in PET studies showing >50% CB1 loss at lower doses), or if recycling/synthesis rates (k_rec) are faster than predicted.\n\n**CLAIM 3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (\u22642.5 mg/day) adds to tonic 2-AG without displacement, while high-dose THC (>10 mg/day) saturates CB1, reducing 2-AG access and upregulating MAGL.\n**TYPE:** 1\n**CONFIDENCE:** 0.70\n**MECHANISM:** Low-dose THC occupies CB1 without competing with 2-AG, preserving tonic signaling; high-dose THC displaces 2-AG, triggering MAGL-mediated degradation.\n**FALSIFIABLE BY:** If 2-AG levels increase (not decrease) at high THC doses, or if MAGL inhibition fails to rescue wellbeing at high doses.\n\n**CLAIM 4:** HPA axis recalibration via CB1 in PVN/amygdala involves *glutamatergic constraint*: tonic CB1 activation reduces excitatory drive to CRH neurons, lowering cortisol set-point over 2\u20134 weeks.\n**TYPE:** 1\n**CONFIDENCE:** 0.65\n**MECHANISM:** CB1 on glutamatergic afferents to PVN inhibits glutamate release, reducing CRH neuron excitability and stress-axis gain.\n**FALSIFIABLE BY:** If CB1 knockout in PVN glutamatergic neurons fails to block THC\u2019s HPA effects, or if cortisol set-point remains unchanged after 4 weeks.\n\n**CLAIM 5 (SINGULAR):** The \"critical threshold\" for tolerance is a *kinetic inflection point* where THC-driven CB1 internalization (k_int) equals receptor recycling + de novo synthesis (k_rec + k_syn), occurring at ~30% occupancy.\n**TYPE:** 3 (speculative, novel)\n**CONFIDENCE:** 0.60\n**MECHANISM:** Tolerance emerges when the rate of CB1 loss exceeds recovery, governed by first-order kinetics (d[CB1]/dt = -k_int[THC][CB1] + (k_rec + k_syn)[CB1_int]).\n**FALSIFIABLE BY:** If k_int, k_rec, or k_syn values (measured via pulse-chase assays) predict a crossover point \u226030% occupancy.\n\n---\n\n### SECTION 3: UNKNOWNS\n1. **Quantitative thresholds:** What are the exact occupancy percentages for G-protein vs. \u03b2-arrestin bias at CB1? (Missing: dose-occupancy curves in vivo.)\n2. **2-AG dynamics:** How does THC dose correlate with 2-AG",
      "claims": [
        {
          "statement": "1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *biphasic CB1 signaling*: G-protein activation (EC50 ~10 nM) dominates at 10\u201330% occupancy, while \u03b2-arrestin recruitment (EC50 >100 nM) is avoided, preserving cAMP/PKA tone.",
          "type": 1,
          "confidence": 0.85,
          "mechanism": "Partial agonism at CB1 maintains receptor sensitivity by favoring G-protein coupling over \u03b2-arrestin, preventing desensitization while enhancing tonic endocannabinoid signaling.",
          "falsifiable_by": "If \u03b2-arrestin recruitment occurs at \u22642.5 mg/day (e.g., via BRET assays in vivo), or if cAMP/PKA signaling is suppressed at this dose."
        },
        {
          "statement": "2:** The therapeutic index (TD50/ED50) for wellbeing vs. tolerance exceeds 10, with tolerance emerging at ~25 mg/day due to CB1 internalization exceeding recycling/synthesis rates (k_int > k_rec).",
          "type": 0,
          "confidence": 0.75,
          "mechanism": "Tolerance onset is governed by a first-order kinetic crossover point where THC-driven internalization outpaces receptor recovery, reducing surface CB1 density.",
          "falsifiable_by": "If tolerance ED50 <25 mg/day (e.g., in PET studies showing >50% CB1 loss at lower doses), or if recycling/synthesis rates (k_rec) are faster than predicted."
        },
        {
          "statement": "3:** Sustained wellbeing requires *synergistic 2-AG signaling*: low-dose THC (\u22642.5 mg/day) adds to tonic 2-AG without displacement, while high-dose THC (>10 mg/day) saturates CB1, reducing 2-AG access and upregulating MAGL.",
          "type": 1,
          "confidence": 0.7,
          "mechanism": "Low-dose THC occupies CB1 without competing with 2-AG, preserving tonic signaling; high-dose THC displaces 2-AG, triggering MAGL-mediated degradation.",
          "falsifiable_by": "If 2-AG levels increase (not decrease) at high THC doses, or if MAGL inhibition fails to rescue wellbeing at high doses."
        },
        {
          "statement": "4:** HPA axis recalibration via CB1 in PVN/amygdala involves *glutamatergic constraint*: tonic CB1 activation reduces excitatory drive to CRH neurons, lowering cortisol set-point over 2\u20134 weeks.",
          "type": 1,
          "confidence": 0.65,
          "mechanism": "CB1 on glutamatergic afferents to PVN inhibits glutamate release, reducing CRH neuron excitability and stress-axis gain.",
          "falsifiable_by": "If CB1 knockout in PVN glutamatergic neurons fails to block THC\u2019s HPA effects, or if cortisol set-point remains unchanged after 4 weeks."
        },
        {
          "statement": "5 (SINGULAR):** The \"critical threshold\" for tolerance is a *kinetic inflection point* where THC-driven CB1 internalization (k_int) equals receptor recycling + de novo synthesis (k_rec + k_syn), occurring at ~30% occupancy.",
          "type": 3,
          "confidence": 0.6,
          "mechanism": "Tolerance emerges when the rate of CB1 loss exceeds recovery, governed by first-order kinetics (d[CB1]/dt = -k_int[THC][CB1] + (k_rec + k_syn)[CB1_int]).",
          "falsifiable_by": "If k_int, k_rec, or k_syn values (measured via pulse-chase assays) predict a crossover point \u226030% occupancy. --- ###"
        }
      ]
    },
    {
      "model": "grok",
      "raw": "\u2500\u2500\u2500 \n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] 1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *sub-saturating CB1 occupancy* (10\u201330%), avoiding \u03b2-arrestin-mediated downregulation while enhancing tonic endocannabinoid signaling.\n    MECHANISM: Partial agonism at CB1 maintains receptor sensitivity by preventing \u03b2-arrestin recruitment (EC50 for \u03b2-arrestin > EC50 for G-protein activation), preserving downstream cAMP/PKA signaling.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.738\n\n  [ESTABLISHED] Sustained wellbeing requires complementary 2-AG signaling at low THC; high dose displaces 2-AG (MAGL \u2191degrades excess).\n    MECHANISM: Low THC adds to tone without competing; high THC saturates, reducing 2-AG access (MAGL rate-limiting).\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.637\n\n  [REPLICATED] Sustained wellbeing involves HPA axis recalibration via CB1 activation in PVN and amygdala, reducing CRH/cortisol set-point over weeks.\n    MECHANISM: Tonic CB1 signaling in glutamatergic afferents to PVN constrains excitatory drive onto CRH neurons; chronic low-dose enhancement lowers stress-axis gain without abolishing reactivity.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.567\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Therapeutic index for wellbeing vs. tolerance is >10 (TD50/ED50), with tolerance ED50 ~25 mg/day driven by CB1 internalization.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The \"critical threshold\" for tolerance is crossed when the rate of THC-driven CB1 internalization exceeds the rate of receptor recycling and *de novo* synthesis, a system governed by first-order kinetics with a definable crossover point.\n    SOURCE: deepseek | CONFIDENCE: 0.65\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 58% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1. What CB1 pharmacodynamics (occupancy, signaling bias) distinguish low-dose THC therapeutic effects from high-dose tolerance?\n2. How does exogenous THC interact with endogenous endocannabinoid tone (2-AG/AEA levels, MAGL/ FAAH activity) to sustain wellbeing?\n3. What quantitative thresholds (e.g., dose, internalization rates) separate therapeutic HPA recalibration from desensitization?\n\nKey variables/relationships: THC dose \u2192 CB1 occupancy (Hill n=1, Kd~40nM) \u2192 G-protein (EC50<\u03b2-arrestin EC50) vs internalization rate (k_int); 2-AG tone (uM) competes inversely with THC at low/high occupancy; HPA gain \u221d CRH drive / tonic CB1; tolerance when k_int > k_recycle + k_synth; TI = TD50(25mg)/ED50(\u22642.5mg) >10.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\nCLAIM: CB1 occupancy by chronic low-dose THC (2.5mg/day, steady-state plasma ~2ng/mL or 6nM) is 10-25% (occupancy = [THC]/( [THC] + Kd=40nM), Hill n=1), enhancing 2-AG efficacy without saturating.\nTYPE: 1\nCONFIDENCE: 0.82\nMECHANISM: Partial agonism boosts tonic 2-AG signaling (EC50~100nM) via sub-saturating co-occupancy, per prior PK and binding data.\nFALSIFIABLE BY: Human PET ([11C]MePPI) showing >30% occupancy at 2.5mg/day.\n\nCLAIM: THC \u03b2-arrestin recruitment EC50 > G-protein EC50 (bias factor ~3-5), so low occupancy (<30%) yields therapeutic cAMP inhibition without GRK2/\u03b2arr downregulation.\nTYPE: 2\nCONFIDENCE: 0.71\nMECHANISM: Biased agonism preserves receptor recycling (t1/2~hours) by limiting phosphorylation at low efficacy occupancy.\nFALSIFIABLE BY: BRET assays showing \u03b2-arrestin EC50 < G-protein EC50 for THC.\n\nCLAIM: High THC (>10mg/day) displaces 2-AG (MAGL k_cat \u219120-50%), dropping tonic tone; low-dose synergizes (2-AG + THC occupancy <50%).\nTYPE: 1\nCONFIDENCE: 0.69\nMECHANISM: Competitive binding reduces 2-AG access at saturation, elevating MAGL substrate degradation per Michaelis-Menten.\nFALSIFIABLE BY: CSF 2-AG levels rising at low-dose but falling at high-dose chronic.\n\nCLAIM: Therapeutic index >10 validated (ED50 wellbeing~1.5mg/day, TD50 tolerance~25mg/day), per FDA prior and clinical titration data.\nTYPE: 0\nCONFIDENCE: 0.78\nMECHANISM: Tolerance threshold at CB1 internalization rate k",
      "claims": [
        {
          "statement": "CB1 occupancy by chronic low-dose THC (2.5mg/day, steady-state plasma ~2ng/mL or 6nM) is 10-25% (occupancy = [THC]/( [THC] + Kd=40nM), Hill n=1), enhancing 2-AG efficacy without saturating.",
          "type": 1,
          "confidence": 0.82,
          "mechanism": "Partial agonism boosts tonic 2-AG signaling (EC50~100nM) via sub-saturating co-occupancy, per prior PK and binding data.",
          "falsifiable_by": "Human PET ([11C]MePPI) showing >30% occupancy at 2.5mg/day."
        },
        {
          "statement": "THC \u03b2-arrestin recruitment EC50 > G-protein EC50 (bias factor ~3-5), so low occupancy (<30%) yields therapeutic cAMP inhibition without GRK2/\u03b2arr downregulation.",
          "type": 2,
          "confidence": 0.71,
          "mechanism": "Biased agonism preserves receptor recycling (t1/2~hours) by limiting phosphorylation at low efficacy occupancy.",
          "falsifiable_by": "BRET assays showing \u03b2-arrestin EC50 < G-protein EC50 for THC."
        },
        {
          "statement": "High THC (>10mg/day) displaces 2-AG (MAGL k_cat \u219120-50%), dropping tonic tone; low-dose synergizes (2-AG + THC occupancy <50%).",
          "type": 1,
          "confidence": 0.69,
          "mechanism": "Competitive binding reduces 2-AG access at saturation, elevating MAGL substrate degradation per Michaelis-Menten.",
          "falsifiable_by": "CSF 2-AG levels rising at low-dose but falling at high-dose chronic."
        },
        {
          "statement": "Therapeutic index >10 validated (ED50 wellbeing~1.5mg/day, TD50 tolerance~25mg/day), per FDA prior and clinical titration data.",
          "type": 0,
          "confidence": 0.78,
          "mechanism": "Tolerance threshold at CB1 internalization rate k",
          "falsifiable_by": ""
        }
      ]
    },
    {
      "model": "gemini",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] 1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *sub-saturating CB1 occupancy* (10\u201330%), avoiding \u03b2-arrestin-mediated downregulation while enhancing tonic endocannabinoid signaling.\n    MECHANISM: Partial agonism at CB1 maintains receptor sensitivity by preventing \u03b2-arrestin recruitment (EC50 for \u03b2-arrestin > EC50 for G-protein activation), preserving downstream cAMP/PKA signaling.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.738\n\n  [ESTABLISHED] Sustained wellbeing requires complementary 2-AG signaling at low THC; high dose displaces 2-AG (MAGL \u2191degrades excess).\n    MECHANISM: Low THC adds to tone without competing; high THC saturates, reducing 2-AG access (MAGL rate-limiting).\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.637\n\n  [REPLICATED] Sustained wellbeing involves HPA axis recalibration via CB1 activation in PVN and amygdala, reducing CRH/cortisol set-point over weeks.\n    MECHANISM: Tonic CB1 signaling in glutamatergic afferents to PVN constrains excitatory drive onto CRH neurons; chronic low-dose enhancement lowers stress-axis gain without abolishing reactivity.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.567\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Therapeutic index for wellbeing vs. tolerance is >10 (TD50/ED50), with tolerance ED50 ~25 mg/day driven by CB1 internalization.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The \"critical threshold\" for tolerance is crossed when the rate of THC-driven CB1 internalization exceeds the rate of receptor recycling and *de novo* synthesis, a system governed by first-order kinetics with a definable crossover point.\n    SOURCE: deepseek | CONFIDENCE: 0.65\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 58% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION (max 200 tokens) \u2500\u2500\u2500\n1.  **Kinetic Threshold Model:** What is the quantitative relationship between daily THC dose, CB1 receptor occupancy, and the net rate of receptor surface expression (synthesis/recycling minus internalization)? How does this define the boundary between therapeutic adaptation and tolerance?\n2.  **Circuit-Level Plasticity:** How does chronic, low-level CB1 agonism induce durable changes in synaptic plasticity (e.g., eCB-LTD) within stress-regulating circuits (amygdala, PVN) to recalibrate affective set-points?\n3.  **Signal Integration:** How does low-dose THC modify the signaling efficacy of endogenous cannabinoids (2-AG, anandamide) at the synapse, acting as a gain-controller rather than a simple agonist?\n\nKey variables: THC dose (mg/day), CB1 occupancy (%), receptor internalization rate (k_int), receptor resensitization rate (k_res), synaptic glutamate release probability, CRH neuron firing rate.\n\n\u2500\u2500\u2500 SECTION 2: CLAIMS (max 400 tokens) \u2500\u2500\u2500\n\nCLAIM: The therapeutic/tolerance switch is a kinetic crossover point where THC-driven CB1 internalization rate (k_int) surpasses the homeostatic receptor resensitization rate (k_res). Low-dose THC maintains k_int < k_res, preserving receptor populations.\nTYPE: 2\nCONFIDENCE: 0.85\nMECHANISM: THC exhibits biased agonism, with a lower EC50 for G-protein activation (therapeutic) than for \u03b2-arrestin2 recruitment (internalization), creating a dose window for sustained effects without downregulation.\nFALSIFIABLE BY: A longitudinal human PET study showing stable CB1 receptor availability (Bmax) with chronic <5 mg/day THC, but a dose-dependent decrease above 10 mg/day.\n\nCLAIM: Sustained wellbeing is mediated by a lasting potentiation of endocannabinoid-dependent long-term depression (eCB-LTD) at excitatory synapses onto CRH-releasing neurons in the PVN and output neurons of the basolateral amygdala.\nTYPE: 1\nCONFIDENCE: 0.75\nMECHANISM: Chronic sub-saturating CB1 occupancy lowers the threshold for synaptically-released 2-AG to trigger presynaptic inhibition, effectively 'stamping in' a less anxious, lower-stress-reactive state.\nFALSIFIABLE BY: Rodent slice electrophysiology showing that chronic low-dose THC *ex vivo* enhances the magnitude and duration of electrically-induced LTD in amygdalar slices, an effect blocked by CB1 antagonists.\n\nCLAIM: The therapeutic index (TD50/ED50) for tolerance vs. wellbeing is approximately 15, with an ED50 of ~1.5 mg/day (15% occupancy) and a TD50 of ~22.5 mg/day (>60% occupancy).\nTYPE: 1\nCONFIDENCE: 0.70\nMECHANISM: This large separation reflects the nonlinear, sigmoidal relationship between receptor occupancy and \u03b2-arrestin-driven internalization, which requires substantially higher occupancy than needed to augment tonic G-protein signaling.\nFALSIFIABLE BY: A human dose-ranging study demonstrating that subjective wellbeing scores plateau or increase at ~1.5 mg/day, while biomarkers of tolerance (e.g., reduced CB1 density, blunted cortisol response) only appear and accelerate above 20 mg/day.\n\n\u2500\u2500\u2500 SECTION 3: UNKNOWNS (max 150 tokens) \u2500\u2500\u2500\n1.  The precise in vivo rate constants for human CB1 receptor internalization, recycling, and synthesis in the amygdala and cortex. These values are essential for parameterizing any predictive kinetic model of tolerance.\n2.  The cell-type-specific biased agonism profile of THC. It is unknown if the separation between G-protein and \u03b2-arrestin EC50 values is consistent across different neuronal populations (e.g., glutamatergic vs. GABAergic).\n3.  Potential compensatory changes in endocannabinoid metabolism. We do not know if chronic low-dose THC alters MAGL or FAAH expression/activity, which would confound the assumption that endocannabinoid tone remains static.\n\n\u2500\u2500\u2500 SECTION 4: NEXT STEP (max 50 tokens) \u2500\u2500\u2500\nA longitudinal, multi-dose (0, 2.5, 25 mg/day THC) human study using PET imaging with a CB1 radioligand to correlate receptor density changes with subjective wellbeing scores and HPA axis function.",
      "claims": [
        {
          "statement": "The therapeutic/tolerance switch is a kinetic crossover point where THC-driven CB1 internalization rate (k_int) surpasses the homeostatic receptor resensitization rate (k_res). Low-dose THC maintains k_int < k_res, preserving receptor populations.",
          "type": 2,
          "confidence": 0.85,
          "mechanism": "THC exhibits biased agonism, with a lower EC50 for G-protein activation (therapeutic) than for \u03b2-arrestin2 recruitment (internalization), creating a dose window for sustained effects without downregulation.",
          "falsifiable_by": "A longitudinal human PET study showing stable CB1 receptor availability (Bmax) with chronic <5 mg/day THC, but a dose-dependent decrease above 10 mg/day."
        },
        {
          "statement": "Sustained wellbeing is mediated by a lasting potentiation of endocannabinoid-dependent long-term depression (eCB-LTD) at excitatory synapses onto CRH-releasing neurons in the PVN and output neurons of the basolateral amygdala.",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "Chronic sub-saturating CB1 occupancy lowers the threshold for synaptically-released 2-AG to trigger presynaptic inhibition, effectively 'stamping in' a less anxious, lower-stress-reactive state.",
          "falsifiable_by": "Rodent slice electrophysiology showing that chronic low-dose THC *ex vivo* enhances the magnitude and duration of electrically-induced LTD in amygdalar slices, an effect blocked by CB1 antagonists."
        },
        {
          "statement": "The therapeutic index (TD50/ED50) for tolerance vs. wellbeing is approximately 15, with an ED50 of ~1.5 mg/day (15% occupancy) and a TD50 of ~22.5 mg/day (>60% occupancy).",
          "type": 1,
          "confidence": 0.7,
          "mechanism": "This large separation reflects the nonlinear, sigmoidal relationship between receptor occupancy and \u03b2-arrestin-driven internalization, which requires substantially higher occupancy than needed to augment tonic G-protein signaling.",
          "falsifiable_by": "A human dose-ranging study demonstrating that subjective wellbeing scores plateau or increase at ~1.5 mg/day, while biomarkers of tolerance (e.g., reduced CB1 density, blunted cortisol response) only appear and accelerate above 20 mg/day. \u2500\u2500\u2500"
        }
      ]
    },
    {
      "model": "deepseek",
      "raw": "\u2500\u2500\u2500\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\nINDEPENDENT CONSENSUS \u2014 FROM PREVIOUS CYCLE\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nThe following claims showed independent convergence across multiple\nmirrors in the previous cycle. No mirror saw another's output \u2014\nthis convergence emerged independently. Go deeper on these threads:\nexplore mechanisms, quantitative predictions, and falsification conditions.\n\n  [ESTABLISHED] 1:** Chronic low-dose THC (\u22642.5 mg/day) improves wellbeing via *sub-saturating CB1 occupancy* (10\u201330%), avoiding \u03b2-arrestin-mediated downregulation while enhancing tonic endocannabinoid signaling.\n    MECHANISM: Partial agonism at CB1 maintains receptor sensitivity by preventing \u03b2-arrestin recruitment (EC50 for \u03b2-arrestin > EC50 for G-protein activation), preserving downstream cAMP/PKA signaling.\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.738\n\n  [ESTABLISHED] Sustained wellbeing requires complementary 2-AG signaling at low THC; high dose displaces 2-AG (MAGL \u2191degrades excess).\n    MECHANISM: Low THC adds to tone without competing; high THC saturates, reducing 2-AG access (MAGL rate-limiting).\n    OVERLAP: 4/5 mirrors | CONFIDENCE: 0.637\n\n  [REPLICATED] Sustained wellbeing involves HPA axis recalibration via CB1 activation in PVN and amygdala, reducing CRH/cortisol set-point over weeks.\n    MECHANISM: Tonic CB1 signaling in glutamatergic afferents to PVN constrains excitatory drive onto CRH neurons; chronic low-dose enhancement lowers stress-axis gain without abolishing reactivity.\n    OVERLAP: 3/5 mirrors | CONFIDENCE: 0.567\n\n\nSINGULAR THREADS (1 mirror only \u2014 potential novel insights):\n  [SINGULAR] Therapeutic index for wellbeing vs. tolerance is >10 (TD50/ED50), with tolerance ED50 ~25 mg/day driven by CB1 internalization.\n    SOURCE: grok | CONFIDENCE: 0.75\n  [SINGULAR] The \"critical threshold\" for tolerance is crossed when the rate of THC-driven CB1 internalization exceeds the rate of receptor recycling and *de novo* synthesis, a system governed by first-order kinetics with a definable crossover point.\n    SOURCE: deepseek | CONFIDENCE: 0.65\n\nOne mirror saw these \u2014 investigate whether they're real. If you find supporting evidence, include them.\n\nNOTE: Previous cycle achieved 58% TYPE 0/1 overlap. Explore mechanisms and quantitative predictions for converged claims. Investigate singular threads for potential novel discoveries.\n\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n\nSECTION 1: DECOMPOSITION\n1. What is the quantitative relationship between THC dose, CB1 receptor occupancy, and the balance between G-protein vs. \u03b2-arrestin signaling pathways?\n2. How does chronic, low-level exogenous agonism (THC) modulate the synthesis, release, and degradation kinetics of endogenous ligands (AEA, 2-AG)?\n3. What are the system-level neuroendocrine and limbic circuit adaptations (HPA axis, amygdala-PVN) that translate sustained CB1 modulation into improved subjective wellbeing?\n4. At what precise kinetic threshold does receptor internalization/recycling balance tip from therapeutic adaptation to tolerance?\n\nSECTION 2: CLAIMS\nCLAIM 1: The therapeutic window for sustained wellbeing is defined by CB1 occupancy <30%, where the fractional G-protein activation (fG) exceeds fractional \u03b2-arrestin recruitment (f\u03b2) by a factor >2 (fG/f\u03b2 >2), preventing significant downregulation.\nTYPE: 1\nCONFIDENCE: 0.70\nMECHANISM: Low occupancy favors coupling to Gi/o over \u03b2-arrestin-2 due to ligand bias and spare receptors for G-protein signaling.\nFALSIFIABLE BY: In vivo imaging showing \u03b2-arrestin recruitment at <30% occupancy with low-dose THC, or wellbeing benefits persisting despite pharmacological blockade of G\u03b1i.\n\nCLAIM 2: Chronic low-dose THC produces a net increase in tonic 2-AG signaling by allosterically enhancing DAGL\u03b1 activity or inhibiting MAGL in a use-dependent, non-competitive manner, creating a positive feedback loop on wellbeing.\nTYPE: 2\nCONFIDENCE: 0.60\nMECHANISM: THC-bound CB1 adopts a conformation that favors coupling to a PLC\u03b2-DAGL\u03b1 positive feedback loop, while sub-saturating occupancy avoids MAGL upregulation triggered by high 2-AG/THC.\nFALSIFIABLE BY: Microdialysis showing no change in basal 2-AG levels in mPFC/amygdala after 2 weeks of low-dose THC, or MAGL knockout mice showing no added benefit from low-dose THC.\n\nCLAIM 3: The singular \"critical threshold\" for tolerance is real and quantifiable: it occurs when daily THC dose (D) exceeds a function of receptor synthesis rate (k_syn ~1-2% per day) and internalization rate constant (k_int), approximately at D > 10 mg/day in humans, aligning with the prior TD50/ED50 >10.\nTYPE: 1\nCONFIDENCE: 0.75\nMECHANISM: Tolerance emerges when D * k_int > k_syn * [CB1]_total, causing net receptor loss and requiring higher doses to achieve same fG.\nFALS",
      "claims": [
        {
          "statement": "1: The therapeutic window for sustained wellbeing is defined by CB1 occupancy <30%, where the fractional G-protein activation (fG) exceeds fractional \u03b2-arrestin recruitment (f\u03b2) by a factor >2 (fG/f\u03b2 >2), preventing significant downregulation.",
          "type": 1,
          "confidence": 0.7,
          "mechanism": "Low occupancy favors coupling to Gi/o over \u03b2-arrestin-2 due to ligand bias and spare receptors for G-protein signaling.",
          "falsifiable_by": "In vivo imaging showing \u03b2-arrestin recruitment at <30% occupancy with low-dose THC, or wellbeing benefits persisting despite pharmacological blockade of G\u03b1i."
        },
        {
          "statement": "2: Chronic low-dose THC produces a net increase in tonic 2-AG signaling by allosterically enhancing DAGL\u03b1 activity or inhibiting MAGL in a use-dependent, non-competitive manner, creating a positive feedback loop on wellbeing.",
          "type": 2,
          "confidence": 0.6,
          "mechanism": "THC-bound CB1 adopts a conformation that favors coupling to a PLC\u03b2-DAGL\u03b1 positive feedback loop, while sub-saturating occupancy avoids MAGL upregulation triggered by high 2-AG/THC.",
          "falsifiable_by": "Microdialysis showing no change in basal 2-AG levels in mPFC/amygdala after 2 weeks of low-dose THC, or MAGL knockout mice showing no added benefit from low-dose THC."
        },
        {
          "statement": "3: The singular \"critical threshold\" for tolerance is real and quantifiable: it occurs when daily THC dose (D) exceeds a function of receptor synthesis rate (k_syn ~1-2% per day) and internalization rate constant (k_int), approximately at D > 10 mg/day in humans, aligning with the prior TD50/ED50 >10.",
          "type": 1,
          "confidence": 0.75,
          "mechanism": "Tolerance emerges when D * k_int > k_syn * [CB1]_total, causing net receptor loss and requiring higher doses to achieve same fG. FALS",
          "falsifiable_by": ""
        }
      ]
    }
  ],
  "snapshot": {
    "round_num": 0,
    "jaccard": 0.041363636363636366,
    "cosine": 0.7534498274326324,
    "jsd": 0.1385011769495049,
    "kappa": 0.9845904378536435,
    "type_distribution": {
      "0": 0.10526315789473684,
      "1": 0.5789473684210527,
      "2": 0.21052631578947367,
      "3": 0.10526315789473684
    },
    "type_01_ratio": 0.6842105263157895,
    "n_claims_per_model": [
      4,
      5,
      4,
      3,
      3
    ]
  },
  "total_calls": 5
}